Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients

Documents similaires

• Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
  par: Inna Y. Gong, et autres
  Publié: (2026)
• CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
  par: J.T. Jutzi, et autres
  Publié: (2025)
• Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
  par: Meirav Kedmi, et autres
  Publié: (2024)
• Correction to “Analysis of 60 Patients with Relapsed or Refractory T‐cell Acute Lymphoblastic Leukemia and T‐cell Lymphoblastic Lymphoma Treated with CD7 ‐targeted Chimeric Antigen Receptor‐T Cell Therapy”
  Publié: (2024)
• Different Epidemiology of Invasive Pulmonary Aspergillosis in Acute Lymphoblastic Leukemia in Comparison With Acute Myeloid Leukemia: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda
  par: C. Cattaneo, et autres
  Publié: (2025)